Abstract:Topic: 22. Stem cell transplantation - Clinical Background: Patients suffering from severe acquired aplastic anemia (SAA) are at a high risk of death without prompt and appropriate treatment. Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has drawn increasing interest as a curative option for SAA. However, graft failure (GF) and severe graft-versus-host disease (GvHD) are two primary obstacles to successful haplo-HSCT. Over decades, G-CSF/ antithymocyte globulin (ATG)-based protocol (the Beijing Protocol) has achieved favorable engraftment and survival outcomes both as an upfront and salvage treatment in SAA patients, whereas the incidence of GvHD is relatively high. Apart from the Beijing Protocol, high-dose post-transplant cyclophosphamide (HD-PTCy, the Baltimore regimen) has been successfully used in haplo-HSCT for SAA, and an inspiring decrease in aGVHD albeit with somewhat high rates of GF has been consecutively reported. Therefore, it is reasonable to modify the current two transplant protocols to exploit their strength and avoid unfavorable conditions. Aims: In this study, we modified the conventional Beijing Protocol: retaining the standard dose of ATG from Beijing protocol to provide sufficient immunosuppression; dividing the full-dose Cy (200 mg/kg in total) was divided into 42.75 mg/kg Cy on day -5 to day -2 and LD-PTCy (14.5 mg/kg on days +3 and +4/+5), hoping to reduce the incidence of severe aGVHD and to guarantee successful and stable engraftment. Methods: Between August 2020 and August 2022, 17 patients diagnosed with SAA accepting haplo-HSCT under the PTCy regimen at Peking University People’s Hospital were enrolled in this study. Here we reported the clinical outcomes of 17 patients who received this modified protocol. Results: Seven patients were males (41.18%) and the median age of these patients was 12 (range, 5-39) years old. The median follow-up was 522 days (range, 138-859 days). No patient developed primary graft failure. All patients achieved neutrophil and platelet engraftment at median times of 12 days (range, 11–20 days) and14 days (range, 8-36 days). During our follow-up, no patients developed grade Ⅲ-Ⅳ aGvHD. The cumulative incidence of grade ⅡaGvHD at 100 days was 23.5% (95% CI, 1.0%-46.0%). Four patients (23.5%) developed chronic GvHD of skin or eyes and all of which were mild. All patients are alive by the end of the follow-up, with a failure-free survival rate of 100%. Four (23.5%) patients developed grade Ⅱ bladder toxicity, two (11.8%) patients developed grade Ⅱ cardiotoxicity. The rate of cytomegalovirus (CMV) reactivation was 82.4% (95% CI, 64.3%-100%). The rate of Epstein-Barr virus (EBV) reactivation was 16.7% (95% CI, 0%-35.7%). No CMV disease and post-transplantation lymphoproliferative disorder (PTLD) occurred among these patients. Summary/Conclusion: In conclusion, our data revealed that it is feasible and effective to use the G-CSF/ATG/LD-PTCy protocol in haplo-HSCT for SAA. With RIC preparative regimen and the use of LD-PTCy, the incidence of severe GVHD was reduced and successful and stable engraftment was achieved.Figure 1 Keywords: Acute graft-versus-host disease, Cyclophosphamide, Aplastic anemia, Haploidentical stem cell transplantation

Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia

Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome

Long-Term Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia Using Melphalan Instead of Cyclophosphamide As a Myeloablative Conditioning Regimen

Outcomes following HSCT using fludarabine replacing cyclophosphamide as a new preconditioning regimen for treatment of hematologic malignancies

Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia

Human leucocyte antigen-matched related haematopoietic stem cell transplantation using low-dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia

Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine And Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission

Efficacy and safety of outpatient fludarabine, cyclophosphamide, and rituximab based allogeneic hematopoietic cell transplantation in adults with severe aplastic anemia

Prospective Study of a Modified Post-Transplantation Cyclophosphamide Regimen for Severe Aplastic Anemia Patients with HLA-Haploidentical Transplantation

Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia

[Acquired severe aplastic anemia in emerging countries: Management from allogeneic hematopoietic cell transplantation indication until post-transplant follow-up SFGM-TC]

Post-transplantation cyclophosphamide and cyclosporine A versus methotrexate and cyclosporine A for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study

Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis

Low-dose Post-Transplant Cyclophosphamide with G-CSF/ATG Based Haploidentical Protocol Provides Favorable Outcomes for SAA Patients.

P1293: LOW-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH G-CSF/ATG BASED HAPLOIDENTICAL PROTOCOL PROVIDES FAVORABLE DECREASE IN ACUTE GRAFT-VERSUS-HOST DISEASE FOR SAA PATIENTS

A Modified Conditioning Regimen Based on Low‐dose Cyclophosphamide and Fludarabine for Haploidentical Hematopoietic Stem Cell Transplant in Severe Aplastic Anemia Patients at Risk of Severe Cardiotoxicity